Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

728
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
728
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

643
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
643
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

751
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
751
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

605
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
605
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Beyond the Tricuspid Envelope: The Utility of TAPSE × PAAT in Advanced Heart Failure".

Echocardiography (Mount Kisco, N.Y.)·2026
Same author

Evaluation of left intraventricular flow dynamics using the novel non-contrast HyperDoppler technique.

European heart journal. Imaging methods and practice·2026
Same author

Nutritional Regulation of Cardiac Metabolism and Function: Molecular and Epigenetic Mechanisms and Their Role in Cardiovascular Disease Prevention.

Nutrients·2026
Same author

Prescriptive appropriateness of echocardiography for the diagnosis of infective endocarditis: an 11-year observational study.

European heart journal. Cardiovascular Imaging·2025
Same author

Adipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia.

Cell death & disease·2025
Same author

Importance of basic science and research training for the future generation of cardiologists.

European heart journal·2025
Same journal

Left ventricular excessive trabeculation: pathophysiology, diagnostic challenges, and prognostic significance.

Heart failure reviews·2026
Same journal

Tachycardia-induced cardiomyopathy: evolution of the concept and contemporary insights.

Heart failure reviews·2026
Same journal

Mavacamten in adolescent obstructive hypertrophic cardiomyopathy: SCOUTing a way forward.

Heart failure reviews·2026
Same journal

Overcoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy.

Heart failure reviews·2026
Same journal

Beyond vasodilation: sotatercept and the remodeling hypothesis in hfpef-associated pulmonary hypertension.

Heart failure reviews·2026
Same journal

Beyond the right ventricle: left heart involvement in pulmonary arterial hypertension.

Heart failure reviews·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K

Current views on anthracycline cardiotoxicity.

Donato Mele1,2, Marianna Nardozza3,4, Paolo Spallarossa5

  • 1Cardiology Unit, Department of Cardiology and LTTA Centre, University Hospital of Ferrara, Ferrara, Italy. donatomele@libero.it.

Heart Failure Reviews
|May 28, 2016
PubMed
Summary
This summary is machine-generated.

Anthracyclines are vital cancer drugs but can cause heart damage (cardiotoxicity). Recent research clarifies their mechanisms, improves early diagnosis, and identifies genetic risks for this chemotherapy side effect.

Keywords:
AnthracyclinesCancerCardiotoxicity

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.4K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.8K

Related Experiment Videos

Last Updated: Mar 20, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.4K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.8K

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Anthracyclines are widely used chemotherapy drugs for various cancers.
  • Anthracycline-induced cardiotoxicity is a significant clinical concern.
  • Understanding and mitigating this side effect is crucial for patient care.

Purpose of the Study:

  • To review current knowledge on anthracycline cardiotoxicity.
  • To highlight recent advances in diagnosis and understanding of its mechanisms.
  • To discuss the role of genetic predisposition in cardiotoxicity.

Main Methods:

  • Review of experimental and clinical investigations.
  • Analysis of molecular mechanisms of cardiotoxicity.
  • Evaluation of advanced noninvasive cardiac imaging techniques.
  • Assessment of genetic profiling data.

Main Results:

  • Elucidation of molecular pathways underlying cardiotoxicity.
  • Improved early detection using advanced cardiac imaging.
  • Identification of genetic factors influencing susceptibility to cardiotoxicity.

Conclusions:

  • Anthracycline cardiotoxicity is a complex issue with advancing diagnostic and mechanistic understanding.
  • Genetic profiling may offer personalized risk assessment for patients.
  • Continued research is vital for developing strategies to prevent or manage cardiotoxicity.